Author reply – Corrected Proof
Beaumont et al and Ueta raise concerns about the systemic safety of aflibercept for intravitreal injection, particularly regarding cerebrovascular risk and stroke, based on their analysis of safety data from the VIEW studies comparing aflibercept to ranibizumab. They acknowledge similar rates of serious adverse events (SAEs) overall between aflibercept and ranibizumab, as well as similar rates of myocardial infarction, stroke, and vascular death as confirmed by masked adjudication using the strict and well-accepted Antiplatelet Trialists' Collaboration (APTC) criteria. However, they focus on numerical imbalances in certain other adverse events (AE) classifications to raise the question of whether aflibercept might be associated (Read more...)